Bangkok Dusit Medical Services Public Company Limited (BDMS), Thailand’s leading private hospital network, has commenced the development of the Bangkok Proton Center at Wattanosoth Cancer Hospital, under the vision of becoming a “Global Destination for the Next Generation of Advanced Cancer Care.” This landmark initiative marks the introduction of proton therapy—one of the most advanced forms of radiation treatment—into Thailand’s private healthcare sector. The project aims to significantly raise the standard of cancer care, enhance treatment outcomes, and improve patients’ quality of life.
The Bangkok Proton Center is being established through a strategic collaboration with Medical Excellence JAPAN (MEJ) and the Economic Research Institute for ASEAN and East Asia (ERIA), with the support of the Government of Japan.
Proton therapy uses high-energy proton particles to precisely target cancer cells. Its distinctive characteristic—delivering maximum energy directly at the intended point—helps spare surrounding healthy tissue, reducing side effects and accelerating recovery. This makes it particularly beneficial for complex and sensitive cancers, including tumors of the brain, spinal cord, and those in pediatric patients.
An Investment in the Future of Thai Healthcare. Dr. Poramaporn Prasarttong-Osoth, President and Senior CEO Group 1 of BDMS, stated: “The Bangkok Proton Center is far more than an investment in equipment—it represents a long-term investment in the health and future of the Thai people. Through our collaboration with ERIA and MEJ, and with the support of the Japanese government, we are bringing world-class, next-generation cancer treatment technology to Thailand to expand treatment options for both Thai and international patients.”
Readiness at Wattanosoth Cancer Hospital. Visiting Prof. Dr. Thiravud Khuhaprema, Director of Wattanosoth Cancer Hospital, added: By adopting Next Generation Proton technology, we are elevating cancer treatment with exceptional precision, enabling more effective tumor targeting while significantly reducing long-term side effects—particularly for high-risk patients and children. Our hospital is fully prepared to integrate this advancement into our 360° Total Cancer Care model, supported by a multidisciplinary team of specialists. This readiness positions us to set a new benchmark for cancer care quality and patient safety in Thailand and across the region.”
Expertise and Regional Cooperation with Japan. Support from the Government of Japan through ERIA plays a vital role in promoting economic and public health cooperation across the region, while MEJ brings Japan’s deep expertise in medical innovation.
Dr. Kenji Shibuya, Chief Executive Officer of MEJ, commented: “Japan is recognized as a global pioneer in proton therapy, with clinical experience dating back to 1983 and 19 operational centers nationwide. We are committed to sharing our expertise with our Thai partners to maximize benefits for patients throughout the region.”
Dr. Manani Uechi, Director of Health Services of ERIA, representing Dr. Tetsuya Watanabe, President of ERIA, stated: “ERIA is pleased to support BDMS in establishing the Proton Therapy Center. This initiative reflects Japan’s commitment to elevating cancer treatment standards across ASEAN and strengthening international healthcare cooperation to ensure broader access to modern, effective therapies.”
Construction of the Bangkok Proton Center, including facility development, equipment installation, and personnel training, is expected to take approximately 3–4 years, with services projected to begin in 2029.
Additional Information
Wattanosoth Cancer Hospital
Wattanosoth Cancer Hospital, established in 2006 under the BDMS Group, is a specialized cancer hospital located at Bangkok Hospital Headquarters. Graciously named “Wattanosoth” (“progressive medicine”) by Her Royal Highness Princess Maha Chakri Sirindhorn, the hospital provides comprehensive care under the 360° Total Cancer Care concept and has treated more than 37,000 new cancer patients. Its multidisciplinary expertise and advanced technologies reinforce its position as a leading cancer care institution in Thailand.
Economic Research Institute for ASEAN and East Asia (ERIA)
Founded in 2007 by leaders of 16 East Asian nations, ERIA is a prominent international policy research organization supporting the ASEAN Community. Its core mission includes advancing regional economic integration, promoting sustainable development, and reducing development disparities across the region.
Medical Excellence JAPAN (MEJ)
MEJ serves as Japan’s central platform for promoting international medical collaboration under the country’s national growth strategy. Working closely with government agencies, medical institutions, academic partners, and industry, MEJ aims to enhance global healthcare partnerships and increase international access to high-quality Japanese medical services.
